肠道微生物影响结直肠癌化疗疗效的研究现状

doi:10.11904/j.issn.1002-3070.2021.05.017

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (5): 476-479.doi: 10.11904/j.issn.1002-3070.2021.05.017

肠道微生物影响结直肠癌化疗疗效的研究现状

韩淑玲, 姚洋, 刘超综述, 张艳桥审校

哈尔滨医科大学附属肿瘤医院消化内科二病房(哈尔滨 150081)

收稿日期:2020-07-21 修回日期:2021-03-05 出版日期:2021-10-28 发布日期:2021-10-25
通讯作者: 张艳桥,E-mail:yanqiaozhang@ems.hrbmu.edu.cn
作者简介:韩淑玲,女,(1994-),硕士研究生,从事消化系统肿瘤的临床研究。

Research status of intestinal microbes affecting the efficacy of chemotherapy for colorectal cancer

HAN Shuling, YAO Yang, LIU Chao, ZHANG Yanqiao

Department of Gastrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2020-07-21 Revised:2021-03-05 Online:2021-10-28 Published:2021-10-25

摘要/Abstract

摘要： 肠道微生物是一个与机体健康密切相关的“生态系统”。一方面,肠道微生物可以为机体提供营养物质、参与机体新陈代谢和免疫调节,抵御病原体、发挥生物屏障功能等。另一方面,肠道微生物及其代谢产物可参与结直肠癌的发生,调节化疗药物及免疫检查点抑制剂作用机制,继而影响化疗及免疫治疗疗效、调节相关不良反应。基于既往大量肠道微生物研究及相关文献,本文将综述肠道微生物影响结直肠癌化疗药物作用机制、疗效的现状,其有望成为提高结直肠癌化疗疗效、降低药物毒副反应的新靶点。

关键词: 肠道微生物, 结直肠癌, 药物作用机制, 疗效

Abstract: Gut microbes are an “ecosystem” closely related to body health.On the one hand,intestinal microbes can provide nutrients for the body,participate in the body's metabolism and immune regulation,resist pathogens,and exert biological barrier functions.On the other hand,intestinal microbes and their metabolites can participate in the occurrence of colorectal cancer,regulate the mechanism of chemotherapy drugs and immune checkpoint inhibitors,then affect the efficacy of chemotherapy and immunotherapy,and regulate related adverse reactions.Based on a large number of previous studies on intestinal microbes and related literatures,this article will review the current status of intestinal microbes affecting the mechanism and efficacy of chemotherapy drugs for colorectal cancer,which is expected to be a new target for improving the treatment of colorectal cancer and reducing the side reaction of the drug toxicity.

Key words: Gut microbes, Colorectal cancer, Mechanism of drug action, Efficacy

中图分类号:

R730.1

韩淑玲, 姚洋, 刘超, 张艳桥. 肠道微生物影响结直肠癌化疗疗效的研究现状[J]. 实用肿瘤学杂志, 2021, 35(5): 476-479.

HAN Shuling, YAO Yang, LIU Chao, ZHANG Yanqiao. Research status of intestinal microbes affecting the efficacy of chemotherapy for colorectal cancer[J]. Journal of Practical Oncology, 2021, 35(5): 476-479.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.05.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I5/476

参考文献

1 Peters BA,Dominianni C,Shapiro JA,et al.The gut microbiota in conventional and serrated precursors of colorectal cancer[J].Microbiome,2016,4(1):69.
2 Ma W,Mao Q,Xia W,et al.Gut microbiota shapes the efficiency of cancer therapy[J].Front Microbiol,2019,10:1050.
3 Hakim H,Dallas R,Wolf J,et al.Gut microbiome composition predicts infection risk during chemotherapy in children with acute lymphoblastic leukemia[J].Clin Infect Dis,2018,67(4):541-548.
4 Scott TA,Quintaneiro LM,Norvaisas P,et al.Host-microbe co-metabolism dictates cancer drug efficacy in C.elegans[J].Cell,2017,169(3):442-456.
5 Degnan PH,Taga ME,Goodman AL.Vitamin B12 as a modulator of gut microbial ecology[J].Cell Metab,2014,20(5):769-778.
6 梁敏.腹腔化疗对直肠癌根治术患者术后早期痛觉敏感性的影响及干预措施研究[D].济南:山东大学,2017.
7 Iida N,Dzutsev A,Stewart CA,et al.Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J].Science,2013,342(6161):967-970.
8 Firwana B,Avaritt N,Shields B,et al.Do checkpoint inhibitors rely on gut microbiota to fight cancer?[J].J Oncol Pharm Pract,2017,24(6):468-472.
9 肖兴鹏.益生菌修复Cr(Ⅵ)和化疗药物奥沙利铂引起的机体损伤和肠道微生物紊乱[D].兰州:兰州大学,2017.
10 Alfredo PP,Jairo PS,Kyle KP,et al.Frontline Science:Microbiota reconstitution restores intestinal integrity after cisplatin therapy[J].J Leukoc Biol,2018,103(5):799-805.
11 Tsuchihashi Y,Abe S,Miyamoto L,et al.Novel hydrophilic camptothecin derivatives conjugated to branched glycerol trimer suppress tumor growth without causing diarrhea in murine xenograft models of human lung cancer[J].Mol Pharm,2020,17(4):1049-1058.
12 Stringer AM,Gibson RJ,Bowen JM,et al.Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile[J].Int J Exp Pathol,2009,90(5):489-499.
13 Stringer AM,Gibson RJ,Logan RM,et al.Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats[J].Cancer Biol Ther,2008,7(12):1919-1925.
14 Lin XB,Dieleman LA,Ali K,et al.Irinotecan(CPT-11)chemotherapy alters intestinal microbiota in tumour bearing rats[J].PLoS One,2012,7(7):e39764.
15 Han SW,Yang X,Pan YF,et al.Effects of postoperative adjuvant chemotherapy and palliative chemotherapy on the gut microbiome in colorectal cancer[J].Microb Pathog,2020,149:104343.
16 姚逸尘.肠道菌群与西妥昔单抗治疗晚期结直肠癌所致皮疹相关性研究[D].福州:福建医科大学,2019.
17 Topalian SL,Taube JM,Anders RA,et al.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J].Nat Rev Cancer,2016,16(5):275.
18 Yadav M,Jhunjhunwala S,Phung QT,et al.Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing[J].Nature,2014,515(7528):572-576.
19 Le DT,Uram JN,Wang H,et al.PD-1 Blockade in Tumors with mismatch-repair deficiency[J].N Engl J Med,2015,372:2509-2520.
20 Santarpia M,Karachaliou N.Tumor immune microenvironment characterization and response to anti-PD-1 therapy[J].Cancer Biol Med,2015,12(2):74-78.
21 Goubet AG,Daillère R,Routy B,et al.The impact of the intestinal microbiota in therapeutic responses against cancer[J].C R Biol,2018,341(5):284-289.
22 Elkrief A,Derosa L,Zitvogel L,et al.The intimate relationship between gut microbiota and cancer immunotherapy[J].Gut Microbes,2019,10(3):424-426.
23 Sivan A,Corrales L,Hubert N,et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J].Science,2015,350:1084-1089.
24 Rescigno M.A 'fit' microbiota to potentiate cancer immunotherapy[J].Genome Med,2015,7(1):1-2.
25 West N,Powrie F.Immunotherapy not working? check your microbiota[J].Cancer Cell,2015,28(6):687-689.
26 Routy B,Gopalakrishnan V,Daillere R,et al.The gut microbiota influences anticancer immunosurveillance and general health[J].Nat Rev Clin Oncol,2018,15(6):382-396.

[1]	黄锐, 刘超, 张艳桥. 辛伐他汀用于结直肠癌治疗的系统综述[J]. 实用肿瘤学杂志, 2021, 35(4): 365-369.
[2]	刘文, 乔文波. 程序性死亡蛋白1及其配体在结直肠癌中的临床研究现状[J]. 实用肿瘤学杂志, 2021, 35(4): 370-375.
[3]	朱公建, 朱奕潼, 丁高恒, 王宏宗, 杜美霞, 刘玉琴. 2009—2015年甘肃省肿瘤登记地区结直肠癌流性特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 212-217.
[4]	董满库, 姜福全, 林海冠, 孙晓敏, 刘景欣, 胡刚, 杨建武. lncRNA BLACAT1靶向LEMD1促进结直肠癌细胞的增殖和转移[J]. 实用肿瘤学杂志, 2020, 34(5): 418-424.
[5]	孙小艳, 张晓艳. LncRNA-SChLAP1在结直肠癌组织中高表达的预后评估意义[J]. 实用肿瘤学杂志, 2020, 34(5): 425-429.
[6]	赵仁成, 林子棠, 余卫军, 雷林, 刘峥, 徐英, 郭艳芳, 彭绩. 2017—2019年深圳市宝安区40~74岁常住居民五癌风险流行状况分析[J]. 实用肿瘤学杂志, 2020, 34(4): 315-320.
[7]	李恒震, 张艳桥. 液体活检在结直肠癌诊断中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(4): 357-361.
[8]	朱晓云, 张亚宁, 马碧萍. 1980—2018年上海市金山区结直肠癌死亡水平及其所致早死概率的趋势分析[J]. 实用肿瘤学杂志, 2020, 34(3): 198-202.
[9]	鲁雪梅, 李云涛, 安锦慧, 季国忠. 溶血磷脂酸在结直肠癌发生发展中的机制研究[J]. 实用肿瘤学杂志, 2020, 34(3): 276-281.
[10]	李斌, 冯保恒, 尹富霞, 苏伟. 建立结直肠癌移植瘤模型研究小鼠肠道中细菌感染情况及地西他滨联合顺铂化疗的作用机制[J]. 实用肿瘤学杂志, 2020, 34(2): 163-168.
[11]	曾理, 庄树彤, 丁世华, 陈冲, 焦璐, 孙大勇. 长链非编码RNA AFAP1-AS1通过PTEN/p-AKT信号通路调控结直肠癌细胞增殖的分子机制研究[J]. 实用肿瘤学杂志, 2020, 34(1): 11-16.
[12]	廖代祥, 郑博, 张彦斌, 于军辉. RRBP1与RABEX-5蛋白在结直肠癌组织中的表达及与临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2020, 34(1): 43-48.
[13]	张景岚, 刘瑞宝. 结直肠癌肝转移瘤局部介入治疗应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 79-82.
[14]	李智杰, 赵琦, 吴华星. 通过宏基因组学研究肠道微生物对结直肠癌患者影响的最新进展[J]. 实用肿瘤学杂志, 2020, 34(1): 93-96.
[15]	夏天一, 张博淼, 姚克非, 崔滨滨. PTPN9表达水平与结直肠癌的临床关系研究[J]. 实用肿瘤学杂志, 2019, 33(5): 415-419.

肠道微生物影响结直肠癌化疗疗效的研究现状

Research status of intestinal microbes affecting the efficacy of chemotherapy for colorectal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价